Volume 90, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Chagas disease, caused by the protozoan parasite , is a major cause of morbidity and mortality in Central and South America. Geographic variations in the sensitivity of serologic diagnostic assays to may reflect differences in exposure. We measured parasite-specific T-cell responses among seropositive individuals in two populations from South America with widely varying antibody titers against . Antibody titers among seropositive individuals were significantly lower in Arequipa, Peru compared with Santa Cruz, Bolivia. Similarly, the proportion of seropositive individuals with positive T-cell responses was lower in Peru than Bolivia, resulting in overall lower frequencies of interferon-γ (IFNγ)-secreting cells from Peruvian samples. However, the magnitude of the IFNγ response was similar among the IFNγ responders in both locations. These data indicate that immunological discrepancies based on geographic region are reflected in T-cell responses as well as antibody responses.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. World Health Organization, 2012. First WHO Report on Neglected Tropical Diseases: Working to Overcome the Global Impact of Neglected Tropical Disease. Available at: http://whqlibdoc.who.int/publications/2010/9789241564090_eng.pdf. Accessed March 20, 2012. [Google Scholar]
  2. Schijman AG, Bisio M, Orellana L, Sued M, Duffy T, Mejia Jaramillo AM, Cura C, Auter F, Veron V, Qvarnstrom Y, Deborggraeve S, Hijar G, Zulantay I, Lucero RH, Velazquez E, Tellez T, Sanchez Leon Z, Galvao L, Nolder D, Monje Rumi M, Levi JE, Ramirez JD, Zorrilla P, Flores M, Jercic MI, Crisante G, Anez N, De Castro AM, Gonzalez CI, Acosta Viana K, Yachelini P, Torrico F, Robello C, Diosque P, Triana Chavez O, Aznar C, Russomando G, Buscher P, Assal A, Guhl F, Sosa Estani S, DaSilva A, Britto C, Luquetti A, Ladzins J, , 2011. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis 5: e931.[Crossref] [Google Scholar]
  3. Afonso AM, Ebell MH, Tarleton RL, , 2012. A systematic review of high quality diagnostic tests for Chagas disease. PLoS Negl Trop Dis 6: e1881.[Crossref] [Google Scholar]
  4. Verani JR, Seitz A, Gilman RH, LaFuente C, Galdos-Cardenas G, Kawai V, de LaFuente E, Ferrufino L, Bowman NM, Pinedo-Cancino V, Levy MZ, Steurer F, Todd CW, Kirchhoff LV, Cabrera L, Verastegui M, Bern C, , 2009. Geographic variation in the sensitivity of recombinant antigen-based rapid tests for chronic Trypanosoma cruzi infection. Am J Trop Med Hyg 80: 410415. [Google Scholar]
  5. Umezawa ES, Luquetti AO, Levitus G, Ponce C, Ponce E, Henriquez D, Revollo S, Espinoza B, Sousa O, Khan B, da Silveira JF, , 2004. Serodiagnosis of chronic and acute Chagas' disease with Trypanosoma cruzi recombinant proteins: results of a collaborative study in six Latin American countries. J Clin Microbiol 42: 449452.[Crossref] [Google Scholar]
  6. Caballero ZC, Sousa OE, Marques WP, Saez-Alquezar A, Umezawa ES, , 2007. Evaluation of serological tests to identify Trypanosoma cruzi infection in humans and determine cross-reactivity with Trypanosoma rangeli and Leishmania spp. Clin Vaccine Immunol 14: 10451049.[Crossref] [Google Scholar]
  7. Sosa-Estani S, Gamboa-Leon MR, Del Cid-Lemus J, Althabe F, Alger J, Almendares O, Cafferata ML, Chippaux JP, Dumonteil E, Gibbons L, Padilla-Raygoza N, Schneider D, Belizan JM, Buekens P, Working G, , 2008. Use of a rapid test on umbilical cord blood to screen for Trypanosoma cruzi infection in pregnant women in Argentina, Bolivia, Honduras, and Mexico. Am J Trop Med Hyg 79: 755759. [Google Scholar]
  8. Delgado S, Castillo Neyra R, Quispe Machaca VR, Ancca Juarez J, Chou Chu L, Verastegui MR, Moscoso Apaza GM, Bocangel CD, Tustin AW, Sterling CR, Comrie AC, Naquira C, Cornejo del Carpio JG, Gilman RH, Bern C, Levy MZ, , 2011. A history of chagas disease transmission, control, and re-emergence in peri-rural La Joya, Peru. PLoS Negl Trop Dis 5: e970.[Crossref] [Google Scholar]
  9. Tustin AW, Small DS, Delgado S, Castillo Neyra R, Verastegui MR, Ancca Juárez JM, Quispe Machaca VR, Gilman RH, Bern C, Levy MZ, , 2012. Use of individual-level covariates to improve latent class analysis of Trypanosoma cruzi diagnostic tests. Epidemiol Method 1: 3354.[Crossref] [Google Scholar]
  10. Hunter GC, Borrini-Mayori K, Ancca Juarez J, Castillo Neyra R, Verastegui MR, Malaga Chavez FS, Cornejo del Carpio JG, Cordova Benzaquen E, Naquira C, Gilman RH, Bern C, Levy MZ, , 2012. A field trial of alternative targeted screening strategies for Chagas disease in Arequipa, Peru. PLoS Negl Trop Dis 6: e1468.[Crossref] [Google Scholar]
  11. Levy MZ, Bowman NM, Kawai V, Plotkin JB, Waller LA, Cabrera L, Steurer F, Seitz AE, Pinedo-Cancino VV, Cornejo del Carpio JG, Cordova Benzaquen E, McKenzie FE, Maguire JH, Gilman RH, Bern C, , 2009. Spatial patterns in discordant diagnostic test results for Chagas disease: links to transmission hotspots. Clin Infect Dis 48: 11041106.[Crossref] [Google Scholar]
  12. Laucella SA, Postan M, Martin D, Hubby Fralish B, Albareda MC, Alvarez MG, Lococo B, Barbieri G, Viotti RJ, Tarleton RL, , 2004. Frequency of interferon- gamma-producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis 189: 909918.[Crossref] [Google Scholar]
  13. Avila HA, Pereira JB, Thiemann O, De Paiva E, DeGrave W, Morel CM, Simpson L, , 1993. Detection of Trypanosoma cruzi in blood specimens of chronic chagasic patients by polymerase chain reaction amplification of kinetoplast minicircle DNA: comparison with serology and xenodiagnosis. J Clin Microbiol 31: 24212426. [Google Scholar]
  14. Salomone OA, Basquiera AL, Sembaj A, Aguerri AM, Reyes ME, Omelianuk M, Fernandez RA, Enders J, Palma A, Barral JM, Madoery RJ, , 2003. Trypanosoma cruzi in persons without serologic evidence of disease, Argentina. Emerg Infect Dis 9: 15581562.[Crossref] [Google Scholar]
  15. Batista AM, Aguiar C, Almeida EA, Guariento ME, Wanderley JS, Costa SC, , 2010. Evidence of Chagas disease in seronegative Brazilian patients with megaesophagus. Int J Infect Dis 14: e974e977.[Crossref] [Google Scholar]
  16. Olivera GC, Albareda MC, Alvarez MG, De Rissio AM, Fichera LE, Cooley G, Yachelini P, Hrellac HA, Riboldi H, Laucella SA, Tarleton RL, Postan M, , 2010. Trypanosoma cruzi-specific immune responses in subjects from endemic areas of Chagas disease of Argentina. Microbes Infect 12: 359363.[Crossref] [Google Scholar]
  17. Ponce C, Ponce E, Vinelli E, Montoya A, de Aguilar V, Gonzalez A, Zingales B, Rangel-Aldao R, Levin MJ, Esfandiari J, Umezawa ES, Luquetti AO, da Silveira JF, , 2005. Validation of a rapid and reliable test for diagnosis of Chagas' disease by detection of Trypanosoma cruzi-specific antibodies in blood of donors and patients in Central America. J Clin Microbiol 43: 50655068.[Crossref] [Google Scholar]
  18. Organizacion Panamericana de la Salud, 2006. Estimacion cuantitativa de la enfermedad de Chagas en las Americas. Montevideo, Uruguay: Organizacion Panamericana de la Salud. [Google Scholar]
  19. Bern C, Montgomery SP, , 2009. An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 49: e52e54.[Crossref] [Google Scholar]
  20. Martin DL, Weatherly DB, Laucella SA, Cabinian MA, Crim MT, Sullivan S, Heiges M, Craven SH, Rosenberg CS, Collins MH, Sette A, Postan M, Tarleton RL, , 2006. CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog 2: e77.[Crossref] [Google Scholar]
  21. Laucella SA, Mazliah DP, Bertocchi G, Alvarez MG, Cooley G, Viotti R, Albareda MC, Lococo B, Postan M, Armenti A, Tarleton RL, , 2009. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis 49: 16751684.[Crossref] [Google Scholar]
  22. Bafica A, Santiago HC, Goldszmid R, Ropert C, Gazzinelli RT, Sher A, , 2006. Cutting edge: TLR9 and TLR2 signaling together account for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection. J Immunol 177: 35153519.[Crossref] [Google Scholar]
  23. Padilla AM, Simpson LJ, Tarleton RL, , 2009. Insufficient TLR activation contributes to the slow development of CD8+ T cell responses in Trypanosoma cruzi infection. J Immunol 183: 12451252.[Crossref] [Google Scholar]
  24. Wherry EJ, Ahmed R, , 2004. Memory CD8 T-cell differentiation during viral infection. J Virol 78: 55355545.[Crossref] [Google Scholar]
  25. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R, , 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 77: 49114927.[Crossref] [Google Scholar]
  26. Bustamante JM, Bixby LM, Tarleton RL, , 2008. Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med 14: 542550.[Crossref] [Google Scholar]
  27. Freeman AJ, Ffrench RA, Post JJ, Harvey CE, Gilmour SJ, White PA, Marinos G, van Beek I, Rawlinson WD, Lloyd AR, , 2004. Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use. J Infect Dis 190: 10931097.[Crossref] [Google Scholar]
  28. Al-Sherbiny M, Osman A, Mohamed N, Shata MT, Abdel-Aziz F, Abdel-Hamid M, Abdelwahab SF, Mikhail N, Stoszek S, Ruggeri L, Folgori A, Nicosia A, Prince AM, Strickland GT, , 2005. Exposure to hepatitis C virus induces cellular immune responses without detectable viremia or seroconversion. Am J Trop Med Hyg 73: 4449. [Google Scholar]
  29. Zeremski M, Shu MA, Brown Q, Wu Y, Des Jarlais DC, Busch MP, Talal AH, Edlin BR, , 2009. Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat 16: 1020.[Crossref] [Google Scholar]
  30. Posavad CM, Wald A, Hosken N, Huang ML, Koelle DM, Ashley RL, Corey L, , 2003. T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity? J Immunol 170: 43804388.[Crossref] [Google Scholar]
  31. Kaul R, Dong T, Plummer FA, Kimani J, Rostron T, Kiama P, Njagi E, Irungu E, Farah B, Oyugi J, Chakraborty R, MacDonald KS, Bwayo JJ, McMichael A, Rowland-Jones SL, , 2001. CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 107: 13031310.[Crossref] [Google Scholar]
  32. Macedo AM, Machado CR, Oliveira RP, Pena SD, , 2004. Trypanosoma cruzi: genetic structure of populations and relevance of genetic variability to the pathogenesis of Chagas disease. Mem Inst Oswaldo Cruz 99: 112.[Crossref] [Google Scholar]
  33. Manoel-Caetano F da S, Silva AE, , 2007. Implications of genetic variability of Trypanosoma cruzi for the pathogenesis of Chagas disease. Cad Saude Publica 23: 22632274.[Crossref] [Google Scholar]
  34. Zafra G, Mantilla JC, Jacome J, Macedo AM, Gonzalez CI, , 2011. Direct analysis of genetic variability in Trypanosoma cruzi populations from tissues of Colombian chagasic patients. Hum Pathol 42: 11591168.[Crossref] [Google Scholar]
  35. Sanchez B, Monteon V, Reyes PA, Espinoza B, , 2001. Standardization of micro-enzyme-linked immunosorbent assay (ELISA) and Western blot for detection of Trypanosoma cruzi antibodies using extracts from Mexican strains as antigens. Arch Med Res 32: 382388.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 02 Jul 2013
  • Accepted : 02 Dec 2013
  • Published online : 04 Jun 2014

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error